We would love for you to become a part of our community. Join our Discord to connect with us and other members!

Ticker
AROC.ST

Price
0.44
Stock movement up
+0.01 (2.80%)
Company name
AroCell AB
Exchange
(ST
,
Currency
SEK
)
Sector
Healthcare >
Diagnostics & Research
Market cap
101.36M
Ent value
69.87M
Price/Sales
1.97
Price/Book
0.78
Div yield
131.82%
Div growth
3.86%
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-13.09%
1 year return
2.33%
3 year return
-22.08%
5 year return
-17.91%
10 year return
-24.72%
Last updated: 2025-01-04

DIVIDENDS

Dividend yield - 5y

Dividend yield data
Dividend per share0.58
Dividend yield131.82%
Payout frequencyQuarterly
Maximum yield174.70%
Average yield119.82%
Minimum yield69.96%
Discount to avg yield9.10%
Upside potential10.01%
Yield as % of max yield75.45%

Yield distribution (inverse percentile) - 5y

Yield distribution data
Dividend yield131.82%
Current yield distribution36.89%
Yield at 100% (Min)69.96%
Yield at 90%87.97%
Yield at 80%98.31%
Yield at 50% (Median)116.00%
Yield at 20%141.46%
Yield at 10%149.48%
Yield at 0% (Max)174.70%

Dividend per share

Dividend per share data
Years of growth-
CCC status-
Dividend per share0.58
Payout frequencyQuarterly
Ex-div date7 Nov 2022
EPS (TTM)-0.22
EPS (1y forward)-0.20
EPS growth (5y)-13.09%
EPS growth (5y forward)-

Dividend growth

Please create a free account or log in to access this chart
Dividend growth data
AROC.STS&P500
DGR MR9.85%12.57%
DGR TTM-6.51%
DGR 3 years1.54%5.24%
DGR 5 years3.86%5.40%
DGR 10 years-7.07%
DGR 15 years-6.12%
Time since last change announced1993 days
EPS growth (5y)-13.09%
EPS growth (5y forward)-

Payout ratio

Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM--
Average--
Forward-290.00%-

VALUATION

Valuation Ratios

Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Valuation (Sales/Book Value) data
Price to Sales1.97
Price to Book0.78
EV to Sales1.35

FINANCIALS

Per share

Per share data
Current share count230.36M
EPS (TTM)-0.22
FCF per share (TTM)-0.06

Income statement

Income statement data
Revenue (TTM)51.58M
Gross profit (TTM)6.46M
Operating income (TTM)-51.87M
Net income (TTM)-50.54M
EPS (TTM)-0.22
EPS (1y forward)-0.20

Margins

Margins data
Gross margin (TTM)12.52%
Operating margin (TTM)-100.55%
Profit margin (TTM)-97.97%

Balance Sheet

Please create a free account or log in to access this chart
Balance Sheet data
Cash44.53M
Net receivables14.43M
Total current assets65.84M
Goodwill69.31M
Intangible assets5.92M
Property, plant and equipment2.18M
Total assets143.26M
Accounts payable4.58M
Short/Current long term debt0.00
Total current liabilities13.04M
Total liabilities13.04M
Shareholder's equity130.21M
Net tangible assets0.00

Cash flow

Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-13.38M
Capital expenditures (TTM)498.00K
Free cash flow (TTM)-13.88M
Dividends paid (TTM)0.00

Financial returns

Please create a free account or log in to access this chart
Financial returns data
Return on Equity-38.81%
Return on Assets-35.28%
Return on Invested Capital-38.81%
Cash Return on Invested Capital-10.66%

STOCK INFORMATION

Stock chart

Stock price data
Open0.43
Daily high0.45
Daily low0.42
Daily Volume265K
All-time high16.42
1y analyst estimate0.90
Beta1.27
EPS (TTM)-0.22
Dividend per share0.58
Ex-div date7 Nov 2022
Next earnings date-

Downside potential

Downside potential data
AROC.STS&P500
Current price drop from All-time high-97.32%-2.61%
Highest price drop-97.98%-56.47%
Date of highest drop21 Mar 20249 Mar 2009
Avg drop from high-70.72%-11.12%
Avg time to new high108 days12 days
Max time to new high2348 days1805 days
COMPANY DETAILS
AROC.ST (AroCell AB) company logo
Marketcap
101.36M
Marketcap category
Small-cap
Description
AroCell AB (publ), a vitro diagnostics company, develops and markets blood and urine sample test products for use in the treatment of breast, prostate, and bladder cancers. The company provides AroCell TK 210 ELISA, an immunoassay kit for the determination of human Thymidine Kinase 1 protein concentration in blood samples; and UBC Rapid for diagnosing and monitoring bladder cancer patients. It also offers TUBEX TF, an in vitro diagnostic test for the detection of acute typhoid fever. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Employees
22
Website
https://www.arocell.com
Investor relations
-
SEC filings
AROC.ST SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
UNDERSTAND THE BUSINESS
COMPANY NEWS
All newsPress releases
No items found
Disclaimer
iO Charts assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
Menu
HomePortfolio ManagementCompany ScreenerGreen InvestmentExchangesContact Us
Language
ENHUNOSVDAFIESDENLFRITPTPLCSSKROELTRRUAF
© 2024 iO Charts All Rights Reserved